ZYBERNO
Stock Report
Updated Aug 24, 2026

AXIM BIOTECHNOLOGIES, INC. (AXIM)

Healthcare • OTC

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
12.0/100
POOR BUSINESS
AXIM BIOTECHNOLOGIES, INC. (AXIM) scores 12/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-4,664.3%)
Return on Capital (Capital Efficiency):CRITICAL (-46.5%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

AXIM BIOTECHNOLOGIES, INC. (AXIM) stock report — Zyberno Score 12/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (1)

Market Cap:$1.00M

Valuation Multiples (2)

P/S Ratio:20.18x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$8.64M

Price Action & Momentum (1)

% of 52-Week High:11.8%
B. Profitability Assessment

Return Metrics (4)

ROA:-104.5%
Reinvestment Rate:24.6%
Fundamental Growth Rate (g):-11.5%

Margin Analysis (3)

Operating Margin Ttm:-4,664.3%
Net Margin Ttm:-8,338.5%
Ebitda Margin:-3,201.9%

TTM Performance (2)

Operating Margin Ttm:-4,664.3%
Net Margin Ttm:-8,338.5%

Yield Metrics (2)

Earnings Yield:-$420.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:38.7%
Latest Earnings Filed:2024-08-19

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):14.1%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.00x
Quick Ratio:0.00x
Cash Ratio:0.00x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-24.07x
Times Interest Earned:-24.07

Capital Structure (4)

Working Capital:-6,552,128.00
Cash And Cash Equivalents:0.00
Long Term Debt:$5.97M
Net Debt:$7.64M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $49.60K
Linear Growth: 14.1%
📊 Click to view full AXIM Revenue analysis & methodology →
Cost Of Revenue Ttm:$6.98K

Profitability Breakdown (2)

$191.42K-$2.31M

Bottom Line Performance (3)

-$4.14M
Income Before Tax:-$4.14M
Ebitda Ttm:-1,588,119.00

Operating Expenses (5)

Operating Expenses:2,404,386.00
R And D Expense:90,644.00
Sga Expense:1,884,097.00
Income Tax Expense:$0.00
Interest Expense:114,305.00

Expense Ratios (3)

R And D To Revenue Percentage:518.6%
Sga To Revenue Percentage:10,779.2%
Ebitda Margin:-3,201.9%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$3.73M
Current Assets:$20.24K
Ppe Net:117,993.00
Goodwill:0.00
Intangible Assets:$3.40M

Liability Structure (4)

Total Liabilities:13,262,485.00
Current Liabilities:6,572,371.00
Long Term Debt:$5.97M
Short Term Debt:$1.67M

Equity & Capital (3)

Equity:-$9.53M
Retained Earnings:-$74.75M
Common Stock:1,000,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:1,673,957.00

Special Items (2)

Contract Liabilities:96,189.00
Stock Based Compensation:9,613.00
C. Cash Flow Analysis

Operating Activities (2)

-$1.14M$0.00

Investment Activities (1)

Investing Cash Flow:-$2.84K

Financing Activities (3)

Financing Cash Flow:$195.60K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:725,361.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.02
-$0.02
Earnings Per Share Ttm:-$0.01

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.00
Operating Cash Flow Per Share:-$0.00

Book Value & Capital (2)

Book Value Per Share:-$0.03
Cash Per Share:-999.00

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.01x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:87,585.19
Cash Conversion Cycle:-89,583.19
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:0.00
Quality Score:15.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:24.6%
Fundamental Growth Rate (g):-11.5%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):14.1%
C. Company Profile & Context

Corporate Information (6)

Symbol:AXIM
Company Name:AXIM BIOTECHNOLOGIES, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:OTC
Country:Unknown

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:294.46M
Shares Outstanding Basic:294.46M
Shares Outstanding Diluted:478.51M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-24 16:29:20 UTC
Data Timestamp:2026-06-24T16:09:55.003871
Scroll to Top